Abbott Laboratories (NYSE: ABT) has been climbing steadily over the past year. The company continues to benefit from strong margins, a dependable revenue base, and improving earnings visibility across its medical device, diagnostics, and nutrition businesses. Shares trade near $128/share, reflecting growing confidence that Abbott can sustain mid single digit growth after a period of volatility.
Recently, Abbott reported results that highlighted ongoing strength in its diabetes and cardiovascular device portfolios. Its FreeStyle Libre platform continues to scale globally, reinforcing Abbott’s position in continuous glucose monitoring. The company also secured new device approvals and stabilized its diagnostics and nutrition segments, showing that execution remains solid even in a mixed healthcare environment.
This article breaks down where analysts believe Abbott could trade by 2027. We pulled together consensus price targets and valuation model inputs to outline the stock’s potential path. These figures reflect analyst expectations and are not TIKR’s predictions.
Find out what a stock’s really worth in under 60 seconds with TIKR’s new Valuation Model (It’s free) >>>
Analyst Price Targets Suggest Modest Upside
Abbott trades near $128/share today. The latest average analyst price target is $145/share, which implies about 13% upside. That places Abbott in the modest upside category, and for investors, this suggests steady but not explosive gains if the company continues delivering consistent results.
Key numbers from the analyst grid:
- Mean target: $145/share
- Median target: $145/share
- High estimate: $162/share
- Low estimate: $122/share
- Ratings: 15 Buys, 6 Outperforms, 6 Holds, 1 Underperform
The spread between the high and low estimates is relatively tight, signaling that analysts broadly agree on Abbott’s predictable trajectory. For investors, this kind of consensus usually points to dependable returns with limited downside as long as the business maintains its margin strength.
Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
Abbott: Growth Outlook and Valuation
Abbott’s long term outlook remains steady, supported by strong operating margins and consistent demand across major franchises. Analysts expect the company to maintain mid single digit revenue growth while continuing to execute efficiently.
Key inputs from the Guided Valuation Model:
- Revenue growth forecast: 7.2%
- Operating margin forecast: 24.3%
- Forward P E multiple used: 22.4x
- Last close: $124/share
- Based on analysts’ average estimates, TIKR’s Guided Valuation Model suggests a value of $150/share by 12/31/27
- That implies about 21% total return, or roughly 9.5% annualized
These numbers indicate steady, predictable compounding rather than rapid acceleration. For investors, this implies that Abbott does not need fast growth to reach the model’s target as long as revenue and margins hold steady.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
What’s Driving the Optimism?
Abbott continues to benefit from strong momentum in several of its core areas. The FreeStyle Libre platform has become a major recurring revenue engine, and cardiovascular devices and diagnostics remain solid contributors. Abbott’s wide product footprint gives it more resilience than companies that rely on a single segment.
Management’s focus on innovation and operational stability is another driver of optimism. The company continues to refresh its device pipeline and strengthen its supply chain. For investors, this combination supports a stable growth profile with healthy profitability.
Bear Case: Slower Growth and Margin Pressure
The main risk for Abbott is the pace of its growth. Mid single digit revenue expansion is solid, but it leaves limited room for error. Slower procedure volumes, pricing pressure in diagnostics, or more intense competition in diabetes care could weigh on results.
Some segments, such as nutrition, may also remain slower growing. If these areas fail to contribute meaningfully, more of the earnings load will fall on devices. For investors, this means upside may remain capped without a clearer catalyst for acceleration.
Outlook for 2027: What Could Abbott Be Worth?
Based on analysts’ average estimates, TIKR’s Guided Valuation Model suggests Abbott could reach about $150/share by 2027. That represents approximately 21% total return from the model’s starting point of $124/share, or about 9.5% annualized.
This outlook reflects steady execution. Revenue is expected to grow about 7.2%, and operating margins are projected to remain near 24.3%, which aligns with Abbott’s historical profile. For investors, the stock appears to offer reliable long term compounding rather than outsized gains.
AI Compounders With Massive Upside That Wall Street Is Overlooking
Everyone wants to cash in on AI. But while the crowd chases the obvious names benefiting from AI like NVIDIA, AMD, or Taiwan Semiconductor, the real opportunity may lie on the AI application layer where a handful of compounders are quietly embedding AI into products people already use every day.
TIKR just released a new free report on 5 undervalued compounders that analysts believe could deliver years of outperformance as AI adoption accelerates.
Inside the report, you’ll find:
- Businesses already turning AI into revenue and earnings growth
- Stocks trading below fair value despite strong analyst forecasts
- Unique picks most investors haven’t even considered
If you want to catch the next wave of AI winners, this report is a must-read.
Find out what your favorite stocks are really worth (Free with TIKR) >>>
